A rare case of osteonecrosis of the jaw related to imatinib
Viviano Massimo, Rossi Marco, Cocca Serena,
소속 상세정보
( Viviano Massimo ) - University of Siena Department of Medical Biotechnologies
( Rossi Marco ) - University of Siena Department of Medicine
( Cocca Serena ) - University of Siena Department of Medicine
KMID : 0355620170430020120
Abstract
Osteonecrosis of the jaw (ONJ) is commonly described as an adverse effect of the use of bisphosphonates. A few cases of ONJ associated with tyrosine kinase inhibitors (sunitinib, imatinib) have been reported in the literature and usually they occurred in patients simultaneously treated with bisphosphonates. We report an atypical case of ONJ related only to imatinib. A 72-year-old male patient was treated with imatinib for metastases from gastrointestinal stromal tumors (GISTs). The patient developed ONJ after 22 months of imatinib only therapy. During his whole life, the patient had never been treated with bisphosphonates or radiotherapy. Microscope examination of the tissues confirmed the clinical diagnosis of diffuse osteonecrosis and showed absence of neoplastic cells. Thus, secondary localisations from GISTs were ruled out. Osteonecrosis of the lower jaw appeared 22 months after initial and exclusive therapy with imatinib. Therefore, imatinib monotherapy can induce ONJ in patients that have never been treated with bisphosphonates or radiotherapy.
키워드
Imatinib mesylate; Osteonecrosis; Oral surgery; Gastrointestinal stromal tumors; Bone remodeling
원문 및 링크아웃 정보
등재저널 정보